Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Evaluating fluid therapy for recovery after head and neck cancer surgery

Official title: Effect of Goal-Directed Fluid Therapy on the Postoperative Outcome in Head and Neck Cancer Surgery: A Randomized Controlled Trial

Run by Beijing Tongren Hospital · NCT06468852 · Data updated 2026-11-12

This study is testing if a special way of giving fluids during surgery can help people recover better after having head and neck cancer surgery.

More Postoperative Complications trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment340 (estimated)
SponsorBeijing Tongren Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedMay 16, 2024
Main results expectedApril 30, 2026
Study endsDecember 31, 2026
Registry record updatedJune 21, 2024
Trial IDNCT06468852 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adult patients scheduled for head and neck cancer surgery lasting two hours or longer who can consent to invasive monitoring.

Probably not a fit

Patients with severe comorbidities, those undergoing palliative surgery, or those requiring emergency procedures may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the effectiveness of goal-directed fluid therapy (GDFT) in improving postoperative recovery for patients undergoing head and neck cancer surgery. Participants will be randomly assigned to receive either GDFT or standard fluid therapy during their surgery. The study will monitor and compare the occurrence of postoperative complications and the length of hospital stays between the two groups. Continuous follow-up will be conducted during hospitalization and after discharge to gather comprehensive data on recovery outcomes.

Why it matters

Potential benefit: If successful, this approach could significantly reduce postoperative complications and improve recovery times for patients undergoing head and neck cancer surgery.

How similar studies have gone: Previous studies have shown that GDFT can reduce postoperative complications in major abdominal surgeries, but its effectiveness in head and neck surgeries remains under investigation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients (Age≥18)
* Scheduled to undergo head and neck cancer surgery (including nasopharyngeal carcinoma, laryngocarcinoma, hypopharyngeal carcinoma, and other head and neck malignancies, but not thyroid cancer) with an expected duration of 2 hours or longer
* Agree to receive invasive artery blood pressure monitoring

Exclusion Criteria:

* American Society of Anesthesiologists (ASA) classification\>Ⅳ
* Palliative surgery was performed for the terminal tumors
* Microlaryngoscopic laser surgery or endoscopic surgery
* Underwent major thoracic or abdominal surgery within 30 days
* Regular renal replacement therapy is required
* NYHA grade\>3 or ejection fraction \<30%
* Lung disease does not tolerate the tidal volume by 8 ml/kg
* Atrial fibrillation
* Unable to give informed consent
* pregnant or lactating woman
* Emergency surgery

Where it's running

  • Beijing tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.